In recent weeks management from Global
Bioenergies (ALGBE: EURONEXT) made the rounds among New
York City investors. The French specialty chemical developer is trying to win
new friends in the U.S. for its bio-isobutene made through the fermentation of
organic materials. Isobutene, also called isobutylene, is a four-molecule
hydrocarbon that is a foundational chemical in a wide range of common products
from gasoline additives to cosmetics. Until recently, isobutene was made
exclusively in the crude oil refinement process. It is one of the many
by-products of crude oil refining that helps pad the profit margins of big oil
and as companies such as ExxonMobile (XOM: NYSE) and Marathon
Petroleum (MRO: NYSE).
The founders of Global Bioenergies, Marc Delcourt
and Philippe Marliére, understood the role of bacteria in accelerating the
breakdown of organic material in nature’s own refinery - fermentation. The
well-known renewable fuel, ethanol, is a typical product of fermentation.
Highly caustic and wanting in efficiency in converting organic matter to power,
ethanol has limitations. The duo wanted to extract more value from organic
feedstock. They also wanted a result that would be compatible with the
entrenched fossil fuel supply chain and distribution network. They set a goal for a biologically-based hydrocarbon.
Bacteria may seem simple, but they are
particular about their living conditions.
It took several years of trial and error before the two scientists
finally coaxed some bacteria into producing isobutene in a gaseous state. It
was a dramatic breakthrough for the specialty chemicals industry that had never
imagined organic hydrocarbons. That might have been the easy part. The years
since have been dedicated to getting the bacteria to live in large colonies
that can produce isobutene at commercial scale.
Patience has paid off. In 2015, Global
Bioenergies completed construction of a pilot plant located at an industrial
site near Reims, Germany. The plant has a capacity of ten metric tons. A
demonstration site with 100 metric tons production capacity was also built at Leuna,
Germany in 2016.
Ready for Commercial Stage
Cristal Union, one of France’s largest
sugar producers, is Global Bioenergies first commercial partner. The two have
formed a joint venture to build a plant with a 50,000 barrel per year nameplate
capacity at one of Cristal’s beet sugar production facilities. The beet sugar
process generates ample waste materials that do not make it into the bags of
beet sugar. The estimated capital cost
to reach commercial production is Euro 115 million, which will be financed
through a mix of construction, equipment and project financing. The partners
are targeting 2021 for the first commercial shipments of isobutene.
The two companies will run the plant as a
joint venture named IBN-One with Global Bioenergies taking the lead in marketing and
distribution. The company sees multiple
markets for its isobutene. The cosmetics
industry makes use of a variety of specialty chemicals for lotions and crèmes
and isobutene is widely used for texturing properties. The high octane character of isobutene also
makes it useful as an additive to gasoline to boost performance of combustion
engines.
Global Bioenergies will earn royalties on
the project with the first Euro 5 million payment is due upon plant completion
and the onset of production. The company wants to cookie cutter the arrangement
around the world with other partners that have a ready source organic material
that might otherwise be considered waste.
Acquiring a Ticket to Go Global
The company is looking well ahead to a mix
of potential partners. The recent
acquisition of Syngip, B.V. with its technology for converting organic material
to fuels is expected to make it possible to use a wide range of feedstocks in
Global Bioenergies’ proprietary fermentation process. The company has already proven is process at
commercial volumes with sugars and cellulosic materials such as straw or wood
chips have been proven compatible in the laboratory.
However, Global Bioenergies wants to use
third-generation feed stocks such as industrial waste gases. Think of the carbon dioxide and carbon
monoxide in the emissions of steel mills.
Syngip’s has developed a process to convert gaseous carbon sources to
light olefins, the foundation for strong, colorfast fibers with a wide range of
uses such as carpeting, ropes or even wallpaper.
As beguiling a concept at waste gas to
carpet might be, a partnership with a major steel producer such as
ArcelorMittal (MT: NYSE) is quite a way
off. Investors should be looking more
closely Global Bioenergies current commercialization efforts. In addition to the joint venture with Cristal
Union to produce isobutene, the company has collaborations underway to reach
end customers: Lantmännen Group’s Aspen, a specialty gasoline
producer; bottled gas maker Butagaz SA owned by DCC, PLC (DCC: LSE); and beauty products developer L’Oreal SA
(OR: EPA). Car manufacturer Audi and specialty chemicals
producer INEOS have also expressed interest in working with Global Bioenergies.
Keys to Success
Turning technology into commercially
viable products and reaching customers requires capital. Global Bioenergies is burning about one
million Euros per month and will probably not become profitable for several
more years. The company recently raised
capital and now has an estimated EURO 19 million (US$24 million) on its balance
sheet. Management expects its nest egg
to support operations and development plans well into 2019. Management has a strong history of successful
capital raising efforts and makes a credible argument that new capital can be
easily raise when needed.
Once commercial production begins, each
joint venture project will have to manage margins between the costs of inputs
and selling prices. Global Bioenergies
expects its bio-isobutene to command premium prices from customers that want to
claim sustainable raw materials in their supply chains. Nonetheless, as a substitute to oil-derived
specialty chemicals, the product will be susceptible to the trend in crude oil
prices. On the input side, sugar prices
will impact the company’s first beet-to-isobutene project in Germany. If successful in making in the leap to cellulosic
or gaseous organic materials, the company may get a break on the cost side from
zero to low cost feedstock from waste emissions or agricultural waste.
A company can stub its toe when taking the
steps from laboratory bench to commercial production and then to the
market. Besides capital and a sound
business model, the right management skills must be deployed. The problem is that each step takes different
talents that are rarely all found a single person. The scientist-product
developer-negotiator-marketer is a rare animal, indeed. Even rarer is the scientist-developer who
understands when to reinforce the team with a qualified negotiator-marketer. Investors will need to watch closely for
early warnings of execution missteps.
Neither the author of the Small Cap Strategist web
log, Crystal Equity Research nor its affiliates have a beneficial interest in
the companies mentioned herein.
1 comment:
Great knowledge About chemics and isobutylene i´m kinda impressed. Thank you for sharing These articles
Post a Comment